Dr. Nancy L. Bartlett
Claim this profileWashington University School of Medicine
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
15 reported clinical trials
32 drugs studied
Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
Stage II
2Non-Hodgkin's Lymphoma
MYC positive
BCL2 positive
BCL6 positive
Affiliated Hospitals
Clinical Trials Nancy L. Bartlett is currently running
Mosunetuzumab
for Aggressive B-Cell Lymphoma
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
Recruiting2 awards Phase 1
Thiotepa + Stem Cell Transplant
for Lymphoma
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk. Autologous stem cell transplantation (ASCT) is standard of care for patients with DLBCL who relapse one year or more after first remission, and it has been shown to improve progression-free survival for patients with primary CNS lymphoma. The four-drug BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) is the preferred conditioning regimen for DLBCL patients undergoing ASCT; however, patients with primary CNS lymphoma receive thiotepa plus carmustine as their conditioning regimen due to its better CNS penetration. This study tests the hypothesis that consolidation thiotepa/carmustine ASCT in first complete remission will reduce the risk of CNS relapse in transplant-eligible patients with DLBCL with no prior CNS disease at high risk of secondary CNS recurrence.
Recruiting1 award Phase 23 criteria
More about Nancy L. Bartlett
Clinical Trial Related6 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Nancy L. Bartlett has experience with
- Nivolumab
- Brentuximab Vedotin
- Rituximab
- Mosunetuzumab
- Dacarbazine
- Cyclophosphamide
Breakdown of trials Nancy L. Bartlett has run
Lymphoma
Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nancy L. Bartlett specialize in?
Nancy L. Bartlett focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Nancy L. Bartlett currently recruiting for clinical trials?
Yes, Nancy L. Bartlett is currently recruiting for 5 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Nancy L. Bartlett has studied deeply?
Yes, Nancy L. Bartlett has studied treatments such as Nivolumab, Brentuximab Vedotin, Rituximab.
What is the best way to schedule an appointment with Nancy L. Bartlett?
Apply for one of the trials that Nancy L. Bartlett is conducting.
What is the office address of Nancy L. Bartlett?
The office of Nancy L. Bartlett is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.